On June 2, 2025, INVO Fertility, Inc. completed the sale of most of its shares in NAYA Therapeutics Inc., formerly a wholly-owned subsidiary, and redeemed its Series C-1 Preferred stock with a conversion price that equates to about 3.23 million shares of NTI's Class A common stock. The company retains 6,300 shares of Series A Preferred Stock, which is 19.9% of NTI's common stock on a converted basis.